Loading stock data…
Catalyst Pharmaceuticals (CPRX)
$31.49
Market Closed
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $149.39M↓ | $152.61M↑ | $148.39M↑ | $146.56M↑ | $141.42M |
| Gross Profit | $134.91M↑ | $126.54M↑ | $125.74M↓ | $125.95M↑ | $123.51M |
| Operating Income | $73.23M↑ | $61.85M↓ | $66.27M | $66.30M↑ | $63.37M |
| Net Income | $63.73M↑ | $52.70M↓ | $52.78M↑ | $52.11M↓ | $56.74M |
Peer Comparison
JNJUNHPFE
Fundamentals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambe...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.84B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.85%
Volume
Today's trading volume
15.51M
Recent News
Why Solaris Energy Infrastructure (SEI) Stock Is Up Today
Shares of mobile power and logistics company Solaris Energy Infrastructure (NYSE:SEI) jumped 5.9% in the afternoon session after S&P Dow Jones Indices announced the company will be added to the S&P SmallCap 600 index.
Sector Update: Energy Stocks Advance Pre-Bell Friday
Energy stocks were advancing pre-bell Friday, with the State Street Energy Select Sector SPDR ETF (X
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger
Catalyst Pharmaceuticals (NASDAQ:CPRX) stockholders approved the company’s proposed merger with Angelini Pharma S.p.A. at a special meeting held virtually on July 8, according to remarks from company officials during the meeting. Patrick J. McEnany, chairman of Catalyst’s board of directors, presid
SEI Stock Jumps 5% After-Hours As S&P 600 Inclusion Sparks Buying
SEI will replace Catalyst Pharmaceuticals in the index, effective prior to the open of trading on Wednesday, July 15.
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.